Neoadjuvant hormone therapy for postmenopausal women with ER [oestrogen receptor] and/or PgR [progesterone receptor] positive primary breast cancer: a multi-center study to determine the optimum length of treatment with letrozole (2.5mg daily) on tumour regression to permit breast conserving surgery.

Trial Profile

Neoadjuvant hormone therapy for postmenopausal women with ER [oestrogen receptor] and/or PgR [progesterone receptor] positive primary breast cancer: a multi-center study to determine the optimum length of treatment with letrozole (2.5mg daily) on tumour regression to permit breast conserving surgery.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Letrozole (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 22 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 19 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top